Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | New therapeutic directions in CTCL

Pierluigi Porcu • 19 Jul 2019
ICML 2019
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Mogamulizumab
MAVORIC

Cutaneous T-cell lymphoma (CTCL) therapy has experienced a boost in recent times, such as the MAVORIC trial that led to the approval of mogamulizumab (NCT01728805). Here, Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, discusses new therapeutic directions in CTCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Pierluigi Porcu

HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial 5:21
HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial
Pierluigi Porcu • 9 Dec 2024
The current standard of care for CTCL 3:46
The current standard of care for CTCL
Pierluigi Porcu • 9 Dec 2024
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD 2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges 3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals